Axogen, Inc. (AXGN)

$6.55

-0.39

(-5.62%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Axogen, Inc.

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 36.16M → 42.92M (in $), with an average increase of 4.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -6.71M → -3.89M (in $), with an average increase of 22.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 61.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 129.3%

Performance

  • $6.49
    $6.93
    $6.55
    downward going graph

    0.92%

    Downside

    Day's Volatility :6.35%

    Upside

    5.48%

    downward going graph
  • $3.45
    $10.83
    $6.55
    downward going graph

    47.33%

    Downside

    52 Weeks Volatility :68.14%

    Upside

    39.52%

    downward going graph

Returns

PeriodAxogen, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-14.74%
-0.7%
0.0%
6 Months
63.29%
6.6%
0.0%
1 Year
-29.54%
3.7%
-1.5%
3 Years
-61.01%
14.0%
-21.8%

Highlights

Market Capitalization
305.8M
Book Value
$2.22
Earnings Per Share (EPS)
-0.51
PEG Ratio
0.0
Wall Street Target Price
13.67
Profit Margin
-13.66%
Operating Margin TTM
-7.44%
Return On Assets TTM
-6.84%
Return On Equity TTM
-22.08%
Revenue TTM
159.0M
Revenue Per Share TTM
3.71
Quarterly Revenue Growth YOY
18.7%
Gross Profit TTM
114.4M
EBITDA
-17.0M
Diluted Eps TTM
-0.51
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.16
EPS Estimate Next Year
0.17
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Axogen, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
10
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 108.7%

Current $6.55
Target $13.67

Company Financials

FY18Y/Y Change
Revenue
83.9M
↑ 38.91%
Net Income
-22.4M
↑ 114.42%
Net Profit Margin
-26.68%
↓ 9.39%
FY19Y/Y Change
Revenue
106.7M
↑ 27.13%
Net Income
-29.1M
↑ 30.03%
Net Profit Margin
-27.29%
↓ 0.61%
FY20Y/Y Change
Revenue
112.3M
↑ 5.24%
Net Income
-24.8M
↓ 14.83%
Net Profit Margin
-22.09%
↑ 5.2%
FY21Y/Y Change
Revenue
127.4M
↑ 13.41%
Net Income
-28.1M
↑ 13.15%
Net Profit Margin
-22.03%
↑ 0.06%
FY22Y/Y Change
Revenue
138.6M
↑ 8.81%
Net Income
-27.3M
↓ 2.59%
Net Profit Margin
-19.72%
↑ 2.31%
FY23Y/Y Change
Revenue
159.0M
↑ 14.74%
Net Income
-21.7M
↓ 20.56%
Net Profit Margin
-13.66%
↑ 6.06%
Q3 FY22Q/Q Change
Revenue
37.0M
↑ 7.27%
Net Income
-3.7M
↓ 49.64%
Net Profit Margin
-9.91%
↑ 11.2%
Q4 FY22Q/Q Change
Revenue
36.2M
↓ 2.15%
Net Income
-5.1M
↑ 40.02%
Net Profit Margin
-14.18%
↓ 4.27%
Q1 FY23Q/Q Change
Revenue
36.7M
↑ 1.38%
Net Income
-6.7M
↑ 30.82%
Net Profit Margin
-18.3%
↓ 4.12%
Q2 FY23Q/Q Change
Revenue
38.2M
↑ 4.07%
Net Income
-6.7M
↓ 0.75%
Net Profit Margin
-17.46%
↑ 0.84%
Q3 FY23Q/Q Change
Revenue
41.3M
↑ 8.17%
Net Income
-4.1M
↓ 38.6%
Net Profit Margin
-9.91%
↑ 7.55%
Q4 FY23Q/Q Change
Revenue
42.9M
↑ 4.0%
Net Income
-3.9M
↓ 4.79%
Net Profit Margin
-9.07%
↑ 0.84%
FY18Y/Y Change
Total Assets
160.2M
↑ 172.06%
Total Liabilities
13.2M
↓ 60.85%
FY19Y/Y Change
Total Assets
154.6M
↓ 3.45%
Total Liabilities
22.5M
↑ 70.5%
FY20Y/Y Change
Total Assets
201.4M
↑ 30.22%
Total Liabilities
78.2M
↑ 247.85%
FY21Y/Y Change
Total Assets
208.0M
↑ 3.3%
Total Liabilities
95.5M
↑ 22.04%
FY22Y/Y Change
Total Assets
195.4M
↓ 6.07%
Total Liabilities
94.4M
↓ 1.14%
FY23Y/Y Change
Total Assets
196.8M
↑ 0.74%
Total Liabilities
101.2M
↑ 7.18%
Q3 FY22Q/Q Change
Total Assets
195.5M
↓ 0.29%
Total Liabilities
94.1M
↓ 0.34%
Q4 FY22Q/Q Change
Total Assets
195.4M
↓ 0.07%
Total Liabilities
94.4M
↑ 0.33%
Q1 FY23Q/Q Change
Total Assets
189.5M
↓ 3.03%
Total Liabilities
92.0M
↓ 2.57%
Q2 FY23Q/Q Change
Total Assets
191.6M
↑ 1.14%
Total Liabilities
94.5M
↑ 2.75%
Q3 FY23Q/Q Change
Total Assets
194.6M
↑ 1.56%
Total Liabilities
96.8M
↑ 2.47%
Q4 FY23Q/Q Change
Total Assets
196.8M
↑ 1.13%
Total Liabilities
101.2M
↑ 4.48%
FY18Y/Y Change
Operating Cash Flow
-17.9M
↑ 93.36%
Investing Cash Flow
-98.2M
↑ 7498.8%
Financing Cash Flow
109.8M
↑ 545.29%
FY19Y/Y Change
Operating Cash Flow
-19.9M
↑ 11.25%
Investing Cash Flow
27.3M
↓ 127.77%
Financing Cash Flow
4.0M
↓ 96.33%
FY20Y/Y Change
Operating Cash Flow
-9.6M
↓ 51.56%
Investing Cash Flow
-17.0M
↓ 162.2%
Financing Cash Flow
40.5M
↑ 904.07%
FY21Y/Y Change
Operating Cash Flow
-13.4M
↑ 39.26%
Investing Cash Flow
-23.6M
↑ 39.42%
Financing Cash Flow
20.5M
↓ 49.47%
FY22Y/Y Change
Operating Cash Flow
-16.1M
↑ 19.85%
Investing Cash Flow
-3.2M
↓ 86.47%
Financing Cash Flow
1.8M
↓ 91.23%
Q3 FY22Q/Q Change
Operating Cash Flow
-689.0K
↓ 87.89%
Investing Cash Flow
3.0M
↑ 30.36%
Financing Cash Flow
215.0K
↓ 67.96%
Q4 FY22Q/Q Change
Operating Cash Flow
1.4M
↓ 297.68%
Investing Cash Flow
-1.2M
↓ 140.69%
Financing Cash Flow
813.0K
↑ 278.14%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.4M
↓ 645.01%
Investing Cash Flow
-786.0K
↓ 34.99%
Financing Cash Flow
633.0K
↓ 22.14%
Q2 FY23Q/Q Change
Operating Cash Flow
292.0K
↓ 103.93%
Investing Cash Flow
14.3M
↓ 1922.14%
Financing Cash Flow
898.0K
↑ 41.86%
Q3 FY23Q/Q Change
Operating Cash Flow
1.6M
↑ 456.85%
Investing Cash Flow
6.0M
↓ 58.15%
Financing Cash Flow
5.0K
↓ 99.44%

Technicals Summary

Sell

Neutral

Buy

Axogen, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Axogen, Inc.
Axogen, Inc.
-9.99%
63.29%
-29.54%
-61.01%
-66.7%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Axogen, Inc.
Axogen, Inc.
NA
NA
0.0
-0.16
-0.22
-0.07
NA
2.22
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Axogen, Inc.
Axogen, Inc.
Buy
$305.8M
-66.7%
NA
-13.66%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    11.95%

  • BlackRock Inc

    7.75%

  • Morgan Stanley - Brokerage Accounts

    7.15%

  • Soleus Capital Management, L.P.

    6.02%

  • Vanguard Group Inc

    5.72%

  • Millennium Management LLC

    3.45%

Corporate Announcements

  • Axogen, Inc. Earnings

    Axogen, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.

Organization
Axogen, Inc.
Employees
426
CEO
Ms. Karen Zaderej
Industry
Health Technology

Discover More

FAQs